Patient Resources
What are clinical trials and who can participate?
Seattle Genetics is focused on generating clinical data that support the utility of our innovative product candidates in improving the treatment and outcomes for patients with cancer. We post clinical trial protocol information for our studies on the National Institutes of Health (NIH) Clinical Trials website at www.clinicaltrials.gov.
For information on other trials sponsored by investigators, search clinicaltrials.gov
Moving from promise to practice in the clinic
Trials by Therapeutic Areas
Hodgkin Lymphoma
- Phase 3 ECHELON-1 trial for patients with advanced classical Hodgkin lymphoma. Study #C25003 [learn more]
- Phase 3 AETHERA trial for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005 [learn more]
- Phase 2 trial for front-line treatment of Hodgkin lymphoma in patients age 60 and above. Study #SGN35-015 [learn more]
- Phase 2 trial for retreatment of Hodgkin lymphoma patients who previously participated in a brentuximab vedotin study. This study is enrolling participants by invitation only. Study #SGN35-006 [learn more]
Non-Hodgkin Lymphoma
- Phase 3 ALCANZA trial for patients with relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 [learn more]
- Phase 3 ECHELON-2 trial for patients with newly diagnosed mature T-cell lymphomas. Study #SGN35-014 [learn more]
- Phase 2 trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. Study #SGN35-012 [learn more]
- Phase 2 trial for retreatment of Hodgkin lymphoma patients who previously participated in a brentuximab vedotin study. This study is enrolling participants by invitation only. Study #SGN35-006 [learn more]
- Phase 1 trial for patients with B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) and highly aggressive lymphomas. Study #SGN19A-0001 [learn more]
- Phase 1 trial for patients with relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-0002 [learn more]
Solid Tumors and Other
- Phase 2 study in patients with CD30-positive malignancies other than lymphoma, including acute lymphoid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and a number of solid tumors. Study #SGN35-013 [learn more]
- Phase 1b study of patients with CD70-positive metastatic renal cell carcinoma (a type of kidney cancer). Study #SGN75-002 [learn more]
- Phase 1 study in patients with pancreatic or gastric adenocarcinoma. Enrollment in this trial is complete. Study #ASG5ME-002 [learn more]
- Phase 1 trial in patients with castration-resistant prostate cancer. Enrollment in this trial is complete. Study #ASG-5ME-10-1 [learn more]
- Phase 1 trial in malignant solid tumors that express Nectin-4. Study #AGS-22M6E-11-1 [learn more]
- Phase 1 trial for patients with B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) and highly aggressive lymphomas. Study #SGN19A-0001 [learn more]
Trials by Program
Brentuximab Vedotin
- Phase 3 ECHELON-1 trial of brentuximab vedotin for front-line treatment in patients with advanced classical Hodgkin lymphoma. Study #C25003 [learn more]
- Phase 3 ECHELON-2 trial of brentuximab vedotin for patients with newly diagnosed mature T-cell lymphomas. Study #SGN35-014 [learn more]
- Phase 3 AETHERA trial for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. Enrollment in this trial is complete. Study #SGN35-005 [learn more]
- Phase 3 ALCANZA trial for patients with relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungoides). Study #C25001 [learn more]
- Phase 2 trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. Study #SGN35-012 [learn more]
- Phase 2 study in patients with CD30-positive malignancies other than lymphoma, including acute lymphoid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and a number of solid tumors. Study #SGN35-013 [learn more]
- Phase 2 trial for front-line treatment of Hodgkin lymphoma in patients age 60 and above. Study #SGN35-015 [learn more]
- Phase 2 trial for retreatment of Hodgkin lymphoma patients who previously participated in a brentuximab vedotin study. This study is enrolling participants by invitation only. Study #SGN35-006 [learn more]
SGN-75
- Phase 1b study to evaluate the safety and tolerability of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma. Study #SGN75-002 [learn more]
ASG-5ME
- Phase 1 study of ASG-5ME in patients with pancreatic or gastric adenocarcinoma. Enrollment in this trial is complete. Study #ASG5ME-002 [learn more]
- Phase 1 trial to evaluate the safety, tolerability and antitumor activity of ASG-5ME, and to identify the maximum tolerated dose in patients with castration-resistant prostate cancer. Enrollment in this trial is complete. Study #ASG-5ME-10-1 [learn more]
ASG-22ME
- Phase 1 trial to evaluate the safety, tolerability and antitumor activity of ASG-22ME in malignant solid tumors that express Nectin-4. Study #AGS-22M6E-11-1 [learn more]
SGN-CD19A
- Phase 1 trial to evaluate the safety, tolerability and antitumor activity of SGN-CD19A in B-lineage acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) and highly aggressive lymphomas. Study #SGN19A-0001 [learn more]
- Phase 1 trial to evaluate the safety, tolerability and antitumor activity of SGN-CD19A in relapsed or refractory B-lineage non-Hodgkin lymphoma. Study #SGN19A-0002 [learn more]